Pharmaceutical Companies

The approval adds a new option in the growing IL-17 inhibitor class and strengthens the company’s dermatology portfolio.

The investment forms part of the company’s broader plan to spend US$55 billion on expanding its domestic manufacturing footprint through 2029.

The partnership grants Lilly global rights to AlzeCure’s preclinical small-molecule candidate, ACD680, which targets the biology of Alzheimer’s disease.

The approval allows the company to market the medicine across all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway, subject to national pricing, reimbursement, and market-access requirements.

The Hatfield facility, located north of London, will undergo a phased upgrade that will significantly expand its manufacturing, packaging and distribution capabilities.

The agreement includes an upfront payment of US$1.25 billion, with additional milestone-based payments of up to US$750 million tied to future sales performance.

The company has invested nearly US$5 billion in the United States over the past 15 years, expanding its manufacturing, research, development, and distribution infrastructure.

The deal integrates Firefly Bio’s experimental Firelink degrader-antibody conjugate platform into J&J’s oncology research and development portfolio, marking a significant step in its long-term strategy to enhance targeted drug delivery systems.

The acquisition comes as GSK intensifies its shift toward oncology to offset expected revenue pressure from upcoming patent expirations in its HIV franchise.

Under the new agreement, EDE and Novo Nordisk will work together to enhance pharmaceutical supply chain security by increasing in-country value creation and expanding strategic partnerships that help maintain a steady supply of medicines.